CAPOZIDE 25/15 (captopril; hydrochlorothiazide) by Bristol Myers Squibb is clinical pharmacology mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 8 more indications. First approved in 1984.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
CAPOZIDE 25/15 is a fixed-dose oral combination of captopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) approved in 1984 for hypertension, heart failure, diabetic nephropathy, and post-MI left ventricular dysfunction. It works by suppressing the renin-angiotensin-aldosterone system through ACE inhibition and promoting sodium/fluid excretion via diuresis. The combination provides synergistic blood pressure reduction with complementary mechanisms.
As LOE approaches, CAPOZIDE brand team faces declining revenue and shrinking headcount; focus shifts to legacy management and generic transition support rather than growth initiatives.
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent…
Worked on CAPOZIDE 25/15 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CAPOZIDE offers limited career growth as the product approaches loss of exclusivity; roles focus on defensive positioning, generic deflection, and transition management rather than innovation or market expansion. This assignment suits professionals seeking stable maintenance roles or those willing to drive creative lifecycle extension strategies (new formulations, patient support programs, indication expansion in underserved markets).